MGB Biopharma and FDA discuss MGB-BP-3 regulatory strategy
9 May 2016 | By Victoria White, Digital Content Producer
MGB Biopharma presented Phase I and preclinical data together with a proposal for the further development of oral MGB-BP-3 in C. difficile infections...